Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018
by from Morbidity and Mortality Weekly Report (MMWR) on (#48670)
Early recombinant zoster vaccine safety monitoring findings are consistent with prelicensure clinical trial data. Serious adverse events were rare, and no unexpected patterns were detected.